For instance, a molecular signature in blood composed of 13 splice variants, including C5ORF4, COPZ1, MACF1, WLS, PRG3, ZNF160, EFTUD2, MAP4K1, MPP1, PKM2, SLC14A1-s, SLC14A1-l and ZNF134, was useful to distinguish PD patients from atypical parkinsonian disorders and healthy controls (HC) nested in the Diagnostic and Prognostic Biomarkers for Parkinson’s Disease (PROBE) with 90% sensitivity and 94% specificity [11]. This evidence concerns the gene EFTUD2 and Parkinson disease.